PT  - JOURNAL ARTICLE
AU  - Bushman, Mary
AU  - Worby, Colin
AU  - Chang, Hsiao-Han
AU  - Kraemer, Moritz
AU  - Hanage, William P.
TI  - Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China
AID  - 10.1101/2020.12.16.20214106
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.12.16.20214106
4099  - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20214106.short
4100  - http://medrxiv.org/content/early/2020/12/18/2020.12.16.20214106.full
AB  - Nonpharmaceutical interventions, such as contact tracing and quarantine, are currently the primary means of controlling the spread of SARS-CoV-2; however, it remains uncertain which interventions are most effective at reducing transmission at the population level. Using serial interval data from before and after the rollout of nonpharmaceutical interventions in China, we estimate that the relative frequency of presymptomatic transmission increased from 34% before the rollout to 71% afterward. The shift touward earlier transmission indicates a disproportionate reduction in transmission post-symptom onset. We estimate that, following the rollout of nonpharmaceutical interventions, transmission post-symptom onset was reduced by 82% whereas presymptomatic transmission decreased by only 16%. These findings suggest that interventions which limit opportunities for transmission in the later stages of infection, such as contact tracing and isolation, may have been particularly effective at reducing transmission of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Allergy and Infectious Diseases (R01AI128344).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Because the data utilized for the current project were not collected specifically for the present study and because no one on the study team had access to identifying data, the study was not considered human subjects research and a Harvard Longwood Campus Institutional Review Board application was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are freely available through Open Science Framework. https://osf.io/ezmkq/